<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>206(5)</volume><submitter>Orozco RMQ</submitter><pubmed_abstract>Bovine mastitis is a frequent infection in lactating cattle, causing great economic losses. &lt;i>Staphylococcus aureus&lt;/i> represents the main etiological agent, which causes recurrent and persistent intramammary infections because conventional antibiotics are ineffective against it. Mastoparan-like peptides are multifunctional molecules with broad antimicrobial potential, constituting an attractive alternative. Nevertheless, their toxicity to host cells has hindered their therapeutic application. Previously, our group engineered three mastoparan-L analogs, namely mastoparan-MO, mastoparan-R1, and [I&lt;sup>5&lt;/sup>, R&lt;sup>8&lt;/sup>] MP, to improve cell selectivity and potential. Here, we were interested in comparing the antibacterial efficacy of mastoparan-L and its analogs against bovine mastiti</pubmed_abstract><journal>Journal of bacteriology</journal><pagination>e0007124</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11112992</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Employment of mastoparan-like peptides to prevent &amp;lt;i&amp;gt;Staphylococcus aureus&amp;lt;/i&amp;gt; associated with bovine mastitis.</pubmed_title><pmcid>PMC11112992</pmcid><pubmed_authors>Oshiro KGN</pubmed_authors><pubmed_authors>Almeida CV</pubmed_authors><pubmed_authors>de Souza CM</pubmed_authors><pubmed_authors>Orozco RMQ</pubmed_authors><pubmed_authors>Macedo MLR</pubmed_authors><pubmed_authors>Franco OL</pubmed_authors><pubmed_authors>Marin VN</pubmed_authors><pubmed_authors>Cardoso MH</pubmed_authors><pubmed_authors>Pinto IB</pubmed_authors><pubmed_authors>Buccini DF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Employment of mastoparan-like peptides to prevent &amp;lt;i&amp;gt;Staphylococcus aureus&amp;lt;/i&amp;gt; associated with bovine mastitis.</name><description>Bovine mastitis is a frequent infection in lactating cattle, causing great economic losses. &lt;i>Staphylococcus aureus&lt;/i> represents the main etiological agent, which causes recurrent and persistent intramammary infections because conventional antibiotics are ineffective against it. Mastoparan-like peptides are multifunctional molecules with broad antimicrobial potential, constituting an attractive alternative. Nevertheless, their toxicity to host cells has hindered their therapeutic application. Previously, our group engineered three mastoparan-L analogs, namely mastoparan-MO, mastoparan-R1, and [I&lt;sup>5&lt;/sup>, R&lt;sup>8&lt;/sup>] MP, to improve cell selectivity and potential. Here, we were interested in comparing the antibacterial efficacy of mastoparan-L and its analogs against bovine mastiti</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2025-04-26T07:51:06.695Z</modification><creation>2025-04-06T12:29:59.193Z</creation></dates><accession>S-EPMC11112992</accession><cross_references><pubmed>38629875</pubmed><doi>10.1128/jb.00071-24</doi></cross_references></HashMap>